Janus Henderson Investors US’s Heron Therapeutics HRTX Stock Holding History

Janus Henderson Investors US’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$82.5M	Buy	5,501,755 +925,948	+20%	+$12.8M	0.07%	330
2016 Q4	$59.9M	Buy	4,575,807 +542,007	+13%	+$8.5M	0.05%	401
2016 Q3	$69.5M	Buy	4,033,800 +19,879	+0.5%	+$369K	0.06%	361
2016 Q2	$72.5M	Buy	4,013,921 +516,166	+15%	+$10.1M	0.06%	356
2016 Q1	$66.4M	Buy	3,497,755 +366,408	+12%	+$7.23M	0.06%	364
2015 Q4	$83.6M	Buy	3,131,347 +549,329	+21%	+$14.7M	0.07%	316
2015 Q3	$63M	Buy	2,582,018 +1,225,944	+90%	+$40.9M	0.06%	369
2015 Q2	$42.3M	Buy	+1,356,074	New	+$25.5M	0.03%	471

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Janus Henderson Investors US's HRTX Position: Q1 2017 in Review

Janus Henderson Investors US increased its Heron Therapeutics (HRTX) stake by 20% in Q1 2017, buying an estimated $12.8M and bringing the position to 5,501,755 shares worth $82.5M. The position accounts for 0.07% of the portfolio, ranked #330.

Janus Henderson Investors US first reported a position in HRTX in Q2 2015 and has held it in 8 quarters since. The position peaked at $83.6M in Q4 2015. 100 funds tracked by Wall St. Rank hold HRTX as of Q1 2017.

Janus Henderson Investors US held 5,501,755 shares of Heron Therapeutics worth $82.5M as of Q1 2017.
Janus Henderson Investors US bought 925,948 Heron Therapeutics shares in Q1 2017, an estimated $12.8M.
Heron Therapeutics made up 0.07% of Janus Henderson Investors US's portfolio in Q1 2017, its #330 holding.
Janus Henderson Investors US first reported a position in Heron Therapeutics in Q2 2015 and has held it in 8 quarters since.
Janus Henderson Investors US's Heron Therapeutics position peaked at $83.6M in Q4 2015.
100 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.